Skip to content
Citation only via Europe PMC

Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling.

Yao C, Cai Z, Song H, Xue Q, Cai B, He W, Kong X, Yang T, Jin J, Li J, Chen B, Zhao F, Chen J, Liu J.

Pharmacological research · 2026

Abstract

The contribution of polyol metabolism to pathological bone remodeling remains incompletely understood. Here, we examined its role in osteoclastogenesis and evaluated the skeletal effects of epalrestat, a clinically approved aldose reductase inhibitor. Exploratory single-cell analysis of two human femoral-head specimens suggested greater macrophage-associated polyol-pathway activity in the osteoporosis specimen. In primary bone marrow-derived macrophages, silencing of Akr1b3 and Sord produced opposing effects on osteoclast differentiation. Epalrestat suppressed RANKL-induced osteoclastogenesis and attenuated bone loss in diabetic, ovariectomy-induced, and inflammatory mouse models under early-intervention regimens. Mechanistic analyses showed improved NADPH/NADP⁺ and GSH/GSSG balance, reduced oxidative stress, and attenuated cytosolic and mitochondrial Ca²⁺ signals and Ca²⁺ oscillations. Genetic and osmotic-compensation experiments further supported a model in which intracellular sorbitol contributes to the osmotic regulation of Ca²⁺ oscillations. Additional findings included reduced inflammation in osteolysis and arthritis models, altered macrophage polarization, and partial preservation of bone marrow vascular features. Together, these findings connect glucose metabolism with redox and Ca²⁺ regulation during osteoclast differentiation and provide a rationale for further evaluation of epalrestat in skeletal disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.1016/j.phrs.2026.109698
Canonical
link ↗
Fetched
2026-10-30 MST

Cite this

APA
C, Y., Z, C., H, S., Q, X., B, C., W, H., X, K., T, Y., J, J., J, L., B, C., F, Z., J, C., &amp; J., L. (2026). Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling. <em>Pharmacological research</em>. https://doi.org/10.1016/j.phrs.2026.109698
Vancouver
C Y, Z C, H S, Q X, B C, W H, et al. Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling. Pharmacological research. 2026. doi:10.1016/j.phrs.2026.109698.
BibTeX
@article{yao2026Polyol, title = {Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling.}, author = {Yao C and Cai Z and Song H and Xue Q and Cai B and He W and Kong X and Yang T and Jin J and Li J and Chen B and Zhao F and Chen J and Liu J.}, journal = {Pharmacological research}, year = {2026}, doi = {10.1016/j.phrs.2026.109698}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings